Jump to content

Ansuvimab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Marshmellowasediting (talk | contribs) at 00:42, 13 August 2019 (Added where mAB114 has shown great success with Ebola.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

mAb114 is a monoclonal antibody that is being evaluated as a treatment for Ebola virus disease.[1] It is based on antibodies originally derived from the blood of a survivor of Ebola virus disease who contracted the disease in Kikwit in 1995.[2] In early 2018, a Phase 1 clinical trial of mAb114[3][4] was conducted by the Vaccine Research Center Clinical Trials Program led by Julie E. Ledgerwood[5]. mAb114 is also being evaluated during the 2018 North Kivu Ebola outbreak.[6]

mAB114 has also shown great success with lowering the mortality rate from 90% to about 34%.

References

  1. ^ "NIH begins testing Ebola treatment in early-stage trial". National Institutes of Health (NIH). 2018-05-23. Retrieved 2018-10-15.
  2. ^ Check Hayden, Erika (2016-02-26). "Ebola survivor's blood holds promise of new treatment". Nature. doi:10.1038/nature.2016.19440. ISSN 1476-4687.
  3. ^ "Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-08-09.
  4. ^ Gaudinski, Martin R.; Coates, Emily E.; Novik, Laura; Widge, Alicia; Houser, Katherine V.; Burch, Eugeania; Holman, LaSonji A.; Gordon, Ingelise J.; Chen, Grace L. (2 March 2019). "Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study". Lancet (London, England). 393 (10174): 889–898. doi:10.1016/S0140-6736(19)30036-4. ISSN 1474-547X. PMC 6436835. PMID 30686586.
  5. ^ "NIH VideoCast - CC Grand Rounds: Response to an Outbreak: Ebola Virus Monoclonal Antibody (mAb114) Rapid Clinical Development". videocast.nih.gov. Retrieved 2019-08-09.
  6. ^ Kingsley-Hall, Alison. "Congo's experimental mAb114 Ebola treatment appears successful: authorities | Central Africa". www.theafricareport.com. Retrieved 2018-10-15.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Ansuvimab&oldid=910573583"